tiprankstipranks
Theralase Technologies (TSE:TLT)
:TLT
Canadian Market
Want to see TSE:TLT full AI Analyst Report?

Theralase Technologies (TLT) Stock Forecast & Price Target

95 Followers
See the Price Targets and Ratings of:

TLT Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Theralase
Technologies
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TLT Stock 12 Month Forecast

There Are No Analyst Ratings for TSE:TLT In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

TLT Financial Forecast

TLT Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

TLT Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Research Capital Analyst forecast on TSE:TLT
Research Capital
Research Capital
C$0.7
Buy
150.00%
Upside
Reiterated
01/15/26
You should know this tiny Canadian biotech stock, analyst saysThe new cohort is expected to enroll approximately 20 patients, initially in the United States, with potential expansion into Canada and other geographies. Enrollment is anticipated to be completed in 2026. While the companies did not disclose who will fund the additional cohort, Uddin said he assumes Theralase will bear the cost and modestly increased his 2026 and 2027 RD expense estimates to reflect the incremental spend.
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Research Capital Analyst forecast on TSE:TLT
Research Capital
Research Capital
C$0.7
Buy
150.00%
Upside
Reiterated
01/15/26
You should know this tiny Canadian biotech stock, analyst saysThe new cohort is expected to enroll approximately 20 patients, initially in the United States, with potential expansion into Canada and other geographies. Enrollment is anticipated to be completed in 2026. While the companies did not disclose who will fund the additional cohort, Uddin said he assumes Theralase will bear the cost and modestly increased his 2026 and 2027 RD expense estimates to reflect the incremental spend.
Stocks with the Highest Top Analyst Consensus in the General Sector
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Theralase Technologies

3 Months
xxx
Success Rate
3/6 ratings generated profit
50%
Average Return
+4.92%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +4.92% per trade.
1 Year
Andre UddinResearch Capital
Success Rate
4/6 ratings generated profit
67%
Average Return
+9.75%
Copying Andre Uddin's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +9.75% per trade.
2 Years
xxx
Success Rate
3/6 ratings generated profit
50%
Average Return
+7.58%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +7.58% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TLT Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
1
1
1
0
0
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
1
1
0
0
In the current month, TLT has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TLT average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

TLT Stock Forecast FAQ

What is TSE:TLT’s average 12-month price target, according to analysts?
Currently, no data Available
What is TSE:TLT’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for TSE:TLT, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is TSE:TLT a Buy, Sell or Hold?
      Currently, no data Available
      What is Theralase Technologies’s price target?
      Currently, no data Available
      What do analysts say about Theralase Technologies?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of TSE:TLT?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.